Stockreport

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time
PDF -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland [Read more]